Neoadjuvant, adjuvant, and perioperative PD-L1 immune checkpoint inhibitors have become standard treatment options for early-stage non-small cell lung cancer, significantly improving survival outcomes compared to conventional approaches.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.